Related coverage linked through entity extraction aliases.
Aug 08, 2026
TAVR panel at CRT 2026 explored the technology's current state and future. CathSAP's latest update includes new guidelines and trials, including EARLY TAVR and FDA approval for asymptomatic severe aortic stenosis.
Jun 05, 2026
Servier will acquire Edgewise Therapeutics' muscular dystrophy business, including the drug sevasemten, for up to $2.65 billion. Sevasemten recently faced an FDA rejection for accelerated approval in Becker muscular dystrophy but is advancing to a Phase 3 trial in 2026. The drug has received multiple FDA and EMA designations for both Becker and Duchenne muscular dystrophy.
Apr 24, 2026
Two studies found cardiac MRI-derived biomarkers may improve heart failure risk assessment. Epicardial adipose tissue index was linked to HFpEF risk, while imaging-derived SvO2 predicted hospitalization and death.
Mar 31, 2026
A study finds nearly half of melanoma patients receiving BRAF or MEK inhibitors develop hypertension or cardiac dysfunction. Moderate to severe cardiac issues appear within 4 weeks and only in patients with medium or higher baseline risk. Higher baseline NT-proBNP levels are associated with increased cardiac dysfunction risk.
Mar 13, 2026
Recent studies examine self-management strategies for breast cancer treatment-related cardiotoxicity and highlight risks of vertebral fractures after discontinuing denosumab therapy in patients receiving aromatase inhibitors.
Feb 17, 2026
The European Commission approved MYQORZO (aficamten) for treating symptomatic obstructive hypertrophic cardiomyopathy in adults, completing global regulatory approvals following FDA and China NMPA clearances. First European launch planned in Germany in Q2 2026.
